Table. Clinical Characteristics of Patients With SBRT-related Fatal Pulmonary Hemorrhage.
| Clinical Scenario | Antiangiogenic Agent (Interval Before/After SBRT, d)a | SBRT Dose, Gy/Fractions, No. | PTV, mL | Maximum Point Dose to PBT, Gy | Other Grade ≥3 Toxic Effects |
|---|---|---|---|---|---|
| Oligometastatic NSCLC | Bevacizumab (14/14) | 45/5 | 100 | 49.4 | None |
| Oligometastatic colorectal cancer | Bevacizumab (6/5) | 50/5 | 95 | 51.4 | None |
| Oligoprogressive NSCLC | Bevacizumab (30/230) | 60/15 | 100 | 65.2 | Grade 4 tracheal necrosis |
| Grade 3 tracheoesophageal fistula | |||||
| Oligometastatic renal cell carcinoma | Pazopanib (30/140) | 60/15 | 335 | 65.9 | Grade 3 pneumomediastinum |
| T2aN0 NSCLC | No | 60/8 | 133 | 63.8 | None |
| Metastatic NSCLC | No | 50/5 | 63 | 55 | None |
Abbreviations: NSCLC, non-small cell lung cancer; PBT, proximal bronchial tree; PTV, planning tumor volume; RT, radiation therapy; SBRT, stereotactic body radiation therapy.
a
Antiangiogenic agents were never given concurrently with SBRT. The interval refers to the elapsed days between the last dose of antiangiogenic agent and the start of SBRT, and the elapsed days between the end of SBRT and the resumption of antiangiogenic agent.